And

are now a part of the new and improved

Advertisement

Topic: Psoriasis

News | June 17, 2019

Lilly: Taltz Tops Adalimumab for PsA in Head-to-Head

Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a...

Read More

News | June 12, 2019

Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCD

Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli...

Read More

News | May 23, 2019

FDA Approves Sorilux for Adolescent Plaque Psoriasis

The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in...

Read More
Features | May 2019

Harnessing the Power of Humor for Psoriasis

Humor can create positive changes in our thoughts, feelings, behaviors, and biochemistry and can also influence how patients cope.
Paul Osincup, MA

Years ago, if someone had told me, as a professional comedian and humorist, that I would author an article in Practical Dermatology®, I would have made a strong wager against it. Back then, I was far too immature to be trusted with...

Read Article

News | April 25, 2019

FDA Approves Ortho Dermatologics' Duobrii for Treatment of Plaque Psoriasis

The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical...

Read More

Advertisement

The Latest in Psoriasis

Advertisement

View more